Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$545 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.5 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
7.9
Industry P/E
--
EV/EBITDA
0.6
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-0.7
Face value
--
Shares outstanding
69,234,096
CFO
$-357.08 Mln
EBITDA
$-396.66 Mln
Net Profit
$-434.90 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Regulus Therapeutics (RGLS)
| 401.3 | 284.5 | 523.6 | 294.0 | 51.9 | 5.1 | -41.1 |
|
BSE Sensex
| 4.3 | 3.9 | 7.7 | 10.3 | 14.5 | 21.5 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|
|
Regulus Therapeutics (RGLS)
| 23.2 | -6.6 | -76.3 | 51.7 | -4.4 | -92.4 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Regulus Therapeutics (RGLS)
|
7.9 | 544.9 | 0.3 | -47.5 | -14,879.4 | -61 | -- | 7.9 |
| 46.7 | 7,725.5 | 1,208.8 | 131.7 | 13.4 | 6.3 | 59.4 | 3.8 | |
| 101.5 | 6,652.0 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 19.4 | |
| 135.0 | 7,049.6 | 4,022.6 | -31.6 | 3.7 | -1.1 | 618.4 | 2.2 | |
| 56.9 | 10,905.2 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.5 | |
| 43.7 | 12,097.3 | 2,298.9 | 643.6 | 27.3 | 29.2 | 20.3 | 5.7 | |
| 53.9 | 6,586.2 | 1,084.3 | 485.4 | 57.0 | 103.8 | 14.2 | 13.6 | |
| 295.8 | 8,785.2 | 2,156.6 | 416.4 | 15.6 | 56.5 | 23.3 | 14.8 | |
| 25.8 | 10,824.9 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
| 120.6 | 12,168.8 | 2,412.6 | 305.8 | 20.5 | 11.6 | 41.7 | 4.8 |
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. The company develops farabursen, an anti-miR... oligonucleotide targeting miR-17 in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. It is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. The company has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc. to develop, manufacture, and commercialize products covered by the licensed patent rights for use in microRNA compounds. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California. Address: 4224 Campus Point Court, San Diego, CA, United States, 92121 Read more
CEO & Director
Mr. Joseph P. Hagan M.B.A.
CEO & Director
Mr. Joseph P. Hagan M.B.A.
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Regulus Therapeutics Inc (RGLS) stood at $ 79 Mln as on 31-Mar-25
The share price of Regulus Therapeutics Inc (RGLS) is $7.92 (NASDAQ) as of 21-May-2025 16:00 EDT. Regulus Therapeutics Inc (RGLS) has given a return of 51.87% in the last 3 years.
Regulus Therapeutics Inc (RGLS) has a market capitalisation of $ 545 Mln as on 20-May-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Regulus Therapeutics Inc (RGLS) is 7.89 times as on 20-May-2025, a 246% premium to its peers’ median range of 2.28 times.
Since, TTM earnings of Regulus Therapeutics Inc (RGLS) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Regulus Therapeutics Inc (RGLS) and enter the required number of quantities and click on buy to purchase the shares of Regulus Therapeutics Inc (RGLS).
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. The company develops farabursen, an anti-miR oligonucleotide targeting miR-17 in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. It is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. The company has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc. to develop, manufacture, and commercialize products covered by the licensed patent rights for use in microRNA compounds. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California. Address: 4224 Campus Point Court, San Diego, CA, United States, 92121
The CEO & director of Mr. Joseph P. Hagan M.B.A.. is Regulus Therapeutics Inc (RGLS), and CFO & Sr. VP is Mr. Joseph P. Hagan M.B.A..
There is no promoter pledging in Regulus Therapeutics Inc (RGLS).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,230
|
|
|
1,176
|
|
|
1,035
|
|
|
929
|
|
|
838
|
|
|
820
|
|
|
750
|
|
|
682
|
|
|
630
|
| Regulus Therapeutics Inc. (RGLS) | Ratios |
|---|---|
|
Return on equity(%)
|
-60.99
|
|
Operating margin(%)
|
-14879.41
|
|
Net Margin(%)
|
-13977.35
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Regulus Therapeutics Inc (RGLS) was $0 Mln.
$-0.03
(
